Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma

Published:2019-09 Issue:9 Volume:39 Page:5149-5156
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

TAKAHASHI AYA,MORIGUCHI MICHIHISA,SEKO YUYA,ISHIKAWA HIROKI,YO TAKAHARU,KIMURA HIROYUKI,FUJII HIDEKI,SHIMA TOSHIHIDE,MITSUMOTO YASUHIDE,ISHIBA HIROSHI,TAKASHIMA HIDETAKA,NAGAO YASUYUKI,JO MASAYASU,ARAI MASAHIRO,HARA TASUKU,OKAJIMA AKIRA,MURAMATSU AKIRA,MORITA ATSUHIRO,YOSHINAMI NAOMI,NAKAJIMA TOMOKI,MITSUYOSHI HIRONORI,UMEMURA ATSUSHI,NISHIKAWA TAICHIRO,YAMAGUCHI KANJI,ITOH YOSHITO

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib;Molecular and Clinical Oncology;2024-07-10

2. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment;Journal of the Formosan Medical Association;2024-07

3. Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial;Lung Cancer;2024-05

4. Characteristics of patients with longer treatment period of lenvatinib for unresectable hepatocellular carcinoma: A post-hoc analysis of post-marketing surveillance study in Japan;PLOS ONE;2024-03-08

5. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma;Targeted Oncology;2024-01